CFT8919
Oncology (specific type not specified)
Phase 1/2Active
Key Facts
About C4 Therapeutics
C4 Therapeutics is dedicated to transforming patient lives by developing a new generation of medicines based on targeted protein degradation (TPD), a therapeutic modality that offers advantages over traditional inhibition. The company's core TORPEDO® platform integrates novel E3 ligase binders and chemical libraries to create selective protein degraders. With key partnerships with Roche, Biogen, and Merck KGaA, and a clinical-stage pipeline led by Cemsidomide, C4T is positioned at the forefront of the TPD field, aiming to address significant unmet needs in oncology and beyond.
View full company profileTherapeutic Areas
Other Oncology (specific type not specified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Cemsidomide | C4 Therapeutics | Phase 1/2 |